Enhance your nephrology practice with CME and tools focused on kidney medicine.
Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
Chee Kay Cheung, MBChB, PhD, FRCP
Claudia Seikrit, MD
Optimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
Brendon Neuen, MBBS, PhD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Reframing IgAN Care: Patient-Centered Strategies to Curb Proteinuria and Preserve Kidney Function
June 05, 2026
Glasgow
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Steven Fishbane, MD
Maurizio Gallieni, MD
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Ellie Kelepouris, MD, FACP, FAHA
Nihar R. Desai, MD, MPH
Improving Sleep and Mental Health in Patients with CKD-aP
Leonie Kraft, MD
Lucio Manenti, MD, PhD
Elevating CKD-aP Care: New Frontier
James Burton, DM, FRCP
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
Patrick Rossignol, MD, PhD
Julio Núñez, MD, PhD
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Jonathan Barratt, MD, PhD
CKD-aP: Beyond the Surface
Kappa-Opioid Settings: Real-World Evidence Insights
Emilio Sanchez, MD, PhD
The Patient-Clinician Connection in Managing CKD-aP
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Javed Butler, MD, MPH, MBA
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
Javed Butler, MD
Treating FSGS: From Steroids to Dual Endothelin Angiotensin Receptor Antagonists and What Comes Next
Kirk Campbell, MD
Jai Radhakrishnan, MD
CKD-aP or Something Else? Decoding the Diagnosis
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
Is CKD-aP Hiding in Your Dialysis Center?
Quantifying CKD-aP: Tools for Better Care
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
Treatment Revolution in IgA Nephropathy
Shikha Wadhwani, MD
Dana Rizk, MD
Potassium Binders: Safety Comes First!
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.